CN113574068B - 诱导抗癌免疫应答的方法 - Google Patents

诱导抗癌免疫应答的方法 Download PDF

Info

Publication number
CN113574068B
CN113574068B CN202080013805.3A CN202080013805A CN113574068B CN 113574068 B CN113574068 B CN 113574068B CN 202080013805 A CN202080013805 A CN 202080013805A CN 113574068 B CN113574068 B CN 113574068B
Authority
CN
China
Prior art keywords
antibody
fold
inhibitor
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080013805.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN113574068A (zh
Inventor
C·D·史密斯
L·W·迈恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogee Biotechnology Corp
Original Assignee
Apogee Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apogee Biotechnology Corp filed Critical Apogee Biotechnology Corp
Publication of CN113574068A publication Critical patent/CN113574068A/zh
Application granted granted Critical
Publication of CN113574068B publication Critical patent/CN113574068B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080013805.3A 2019-01-16 2020-01-16 诱导抗癌免疫应答的方法 Active CN113574068B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962792996P 2019-01-16 2019-01-16
US62/792,996 2019-01-16
PCT/US2020/013817 WO2020150434A1 (en) 2019-01-16 2020-01-16 Methods of inducing an anti-cancer immune response

Publications (2)

Publication Number Publication Date
CN113574068A CN113574068A (zh) 2021-10-29
CN113574068B true CN113574068B (zh) 2024-07-23

Family

ID=71613420

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080013805.3A Active CN113574068B (zh) 2019-01-16 2020-01-16 诱导抗癌免疫应答的方法

Country Status (11)

Country Link
US (1) US20220062250A1 (cg-RX-API-DMAC10.html)
EP (1) EP3911681A4 (cg-RX-API-DMAC10.html)
JP (1) JP7693206B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210118101A (cg-RX-API-DMAC10.html)
CN (1) CN113574068B (cg-RX-API-DMAC10.html)
AU (1) AU2020208414B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021013952A2 (cg-RX-API-DMAC10.html)
CA (1) CA3126818A1 (cg-RX-API-DMAC10.html)
IL (1) IL284695A (cg-RX-API-DMAC10.html)
MX (1) MX2021008591A (cg-RX-API-DMAC10.html)
WO (1) WO2020150434A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220160692A1 (en) * 2019-04-09 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
US20240052050A1 (en) * 2020-12-16 2024-02-15 Merus N.V. Multispecific antibodies for the treatment of cancer
CN116217468A (zh) * 2023-02-22 2023-06-06 天津民祥药业有限公司 一种奥帕尼布的新型合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248041A (zh) * 2005-06-17 2008-08-20 艾宝奇生物工艺有限公司 鞘氨醇激酶抑制剂
WO2017129769A1 (en) * 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263344B2 (en) * 2006-09-08 2012-09-11 Institut Gustave Roussy Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment
CA2748546A1 (en) * 2008-12-30 2010-07-08 Musc Foundation For Research Development Sphingo-guanidines and their use as inhibitors of sphingosine kinase
CA2997671A1 (en) 2015-10-06 2017-04-13 Redhill Biopharma Ltd. Combination therapies for treating cancer
WO2018237379A2 (en) * 2017-06-23 2018-12-27 Enzo Biochem, Inc. Sphingosine pathway modulating compounds for the treatment of cancers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248041A (zh) * 2005-06-17 2008-08-20 艾宝奇生物工艺有限公司 鞘氨醇激酶抑制剂
WO2017129769A1 (en) * 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Molecular therapies and precision medicine for hepatocellular carcinoma;Josep M. Llovet等;《Nature Reviews Clinical Oncology》;第15卷(第10期);599-616 *
The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo;Lu Dai等;《International Journal of Cancer》;第142卷(第10期);2153-2162 *
The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo;Heather Venant等;《Molecular Cancer Therapeutics》;第14卷(第12期);2744-2752 *

Also Published As

Publication number Publication date
BR112021013952A2 (pt) 2021-11-16
AU2020208414B2 (en) 2026-05-21
AU2020208414A1 (en) 2021-07-29
CN113574068A (zh) 2021-10-29
US20220062250A1 (en) 2022-03-03
CA3126818A1 (en) 2020-07-23
EP3911681A1 (en) 2021-11-24
WO2020150434A1 (en) 2020-07-23
EP3911681A4 (en) 2022-11-02
MX2021008591A (es) 2021-10-13
IL284695A (en) 2021-08-31
KR20210118101A (ko) 2021-09-29
JP2022517415A (ja) 2022-03-08
JP7693206B2 (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
JP6894952B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
JP6248024B2 (ja) ヒトｏｘ４０受容体に対する結合分子
JP6552621B2 (ja) 抗ｐｄ−１抗体およびその使用方法
CN109890387B (zh) 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
US10465009B2 (en) BCMA antigen binding proteins
JP7455806B2 (ja) キノリン誘導体と抗体による薬物の組み合わせ
US20210171647A1 (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
CN104829718A (zh) 前列腺素e2结合蛋白及其用途
TW201536318A (zh) 治療偶發性包涵體肌炎之方法
BR112021011393A2 (pt) Anticorpos anti-il-27 e usos dos mesmos
JP7328983B2 (ja) 抗ｉｌ－２７抗体及びその使用
TW201834697A (zh) Her2標靶抗體－藥物結合物之組合療法
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
AU2020208414B2 (en) Methods of inducing an anti-cancer immune response
HK40056021A (en) Methods of inducing an anti-cancer immune response
HK40056021B (en) Methods of inducing an anti-cancer immune response
AU2023269154B2 (en) Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist
WO2020119792A1 (en) Humanized antibodies against ox40, method for preparing the same, and use thereof
CN115697374A (zh) 用于治疗胶质母细胞瘤的方法
HK40088121A (en) Methods for treating glioblastoma
HK40044333A (en) Drug combination of quinoline derivative and antibody
JPWO2019049956A1 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40056021

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant